Evaluating Androgen Receptor Inhibition Combined with Hormonal Therapies in Recurrent Adult-Type Ovarian Granulosa Cell Tumor: Insights from a Phase II Study
Posted innews OB/GYN & Women’s Health Oncology

Evaluating Androgen Receptor Inhibition Combined with Hormonal Therapies in Recurrent Adult-Type Ovarian Granulosa Cell Tumor: Insights from a Phase II Study

A Phase II trial assessed the combination of darolutamide, leuprolide acetate, and exemestane in recurrent adult-type ovarian granulosa cell tumor, showing limited objective response but clinically meaningful progression-free survival without severe toxicity.
Enhanced Gynecologic Oncology Decision Support: Impact of Guideline-Anchored Retrieval-Augmented Generation Versus Baseline and Literature-Based AI Models
Posted innews OB/GYN & Women’s Health Oncology

Enhanced Gynecologic Oncology Decision Support: Impact of Guideline-Anchored Retrieval-Augmented Generation Versus Baseline and Literature-Based AI Models

A study benchmarking large language models in gynecologic oncology demonstrates that guideline-anchored retrieval-augmented generation (RAG) configurations outperform baseline and literature-only AI systems in clinical decision support, highlighting the critical role of direct guideline integration.
Dual Immune Checkpoint Inhibition with Cemiplimab and Fianlimab Enhances Neoadjuvant Chemotherapy Response in Early-Stage High-Risk ERBB2-Negative Breast Cancer: Insights from the I-SPY2 Trial
Posted innews OB/GYN & Women’s Health Oncology

Dual Immune Checkpoint Inhibition with Cemiplimab and Fianlimab Enhances Neoadjuvant Chemotherapy Response in Early-Stage High-Risk ERBB2-Negative Breast Cancer: Insights from the I-SPY2 Trial

The I-SPY2 trial shows that combining PD-1 and LAG-3 inhibitors with neoadjuvant chemotherapy significantly improves pathologic complete response rates in early-stage high-risk ERBB2-negative breast cancer, especially in patients with a positive immune signature.